Compare ADMA Biologics Inc (ADMA) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs PepsiCo, Inc. — how do they compare? ADMA Biologics Inc trades at $9.27 (market cap $2.13B), while PepsiCo, Inc. trades at $143.7 (market cap $198.15B). The key difference: PepsiCo, Inc. is far larger — about 93× ADMA Biologics Inc's market cap, and PepsiCo, Inc. pays a 4.08% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | PEP | |
|---|---|---|
Market Cap | $2.13B | $198.15B |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $170.44 |
52-Week Low | $7.60 | $133.81 |
Enterprise Value | $2.20B | $240.05B |
Dividend Yield | — | 4.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
PepsiCo (PEP) trades at $143.66, up 0.26% on the day, with a bullish technical signal and strong profitability metrics including a 54.06% gross margin and 43.92% ROE. Recent earnings have consistently beaten estimates, and the company maintains a solid cash flow profile. News highlights a strategic price reduction on snacks to address consumer pushback and a focus on North American recovery.
The outlook is positive with a consensus price target of $161.73, implying potential upside. Key risks include competitive pressures and sensitivity to consumer spending. Analyst sentiment is mixed but leans bullish, supported by institutional accumulation and a sustainable dividend yield near 4%.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
